+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-03-28Number of Pages: 114

Preimplantation Genetic Diagnosis Market - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Rising numbers of assisted reproductive procedures such as in vitro fertilization (IVF) is Asia is the most prominent factor driving the market for preimplantation genetic diagnosis. This is, in essence, the result of factors such as the delayed age of conception among Asian women, the rising rate of infertility among the population, and the significantly expanding medical tourism industry in the region. Rising disposable incomes and increased awareness regarding the rising prevalence of a number of genetic disorders are also encouraging the Asian population to undertake costly diagnostic procedures such as PGD.

TMR analysts project that these factors will enable the Asia preimplantation genetic diagnosis market expansion at a healthy 6.8% CAGR from 2015 to 2023. The market is expected to rise from a valuation of US$16.0 mn in 2014 to US$28.8 mn by 2023.

Rising Preference for Single Gene Disorder Screening over Prenatal Diagnostic Testing to Drive Market

Preimplantation genetic diagnosis for the screening of aneuploidy held the largest share of 34.7% in the Asia PGD market in 2014. Liberal regulations pertaining to this area of diagnosis in most Asian countries is the major factor behind the high numbers of aneuploidy screening tests undertaken every year in the region. However, PGD for single gene disorder is projected to expand at the faster CAGR of 8.4% from the period between 2015 and 2023.

Increased preference of this diagnostic modality is encouraged by technological advancements and relatively high accuracy of results. Moreover, single gene disorder screening is more beneficial compared to conventional prenatal diagnostic testing in embryo, driving the market for PGD for single gene disorder.

 

preimplantation-genetic-diagnosis-market

 

Rising Numbers of Healthcare Facilities to Boost Asia PGD Market

Known to provide excellent medical services at highly economical rates as compared to developed regions, the healthcare industry in Asia has invited patients from world over. With continuous advancements in healthcare infrastructure, rising numbers of healthcare experts, and constantly improving diagnostic facilities, Asia is expected to be a major hub for the PGD market in the future. Many global vendors in the healthcare and diagnostics industry are extending their businesses in the region and the number of fertility clinics, hospitals, and diagnostic centers are constantly rising in the region.

Fertility clinics held a major share in the overall Asia PGD market in 2014, and are expected to exhibit a 5.9% CAGR from the period between 2015 and 2023. However, the segment of healthcare facilities is expected to expand at a much better 7.8% CAGR over the same period. The flourishing tourism industry in the region is leading to the establishment of an increasing number of IVF centers and healthcare facilities such as hospitals and diagnostic centers in the region.

Asia PGD Market to Witness Highest Traction in Southern Countries

In the next few years, the Asia PGD market is expected to witness the highest growth in Southern countries such as India and China. The high and rising rate of infertility in South Asian countries, rising disposable incomes, high percentage of women in the workforce, and availability of technologically advanced healthcare infrastructure will enable the region in presenting the most attractive growth opportunities for the Asia PGD market. Countries in Southern Asia will also benefit from the flourishing medical tourism industry during the period between 2015 and 2023.


Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Asia Preimplantation Genetic Diagnosis (PGD): Market Overview
3.1 Introduction
3.2 Market Dynamics
     3.2.1 Drivers
     3.2.2 Restraints
     3.2.3 Opportunities
3.3 Porter’s Five Forces Analysis
     3.3.1 Bargaining Power of Suppliers
     3.3.2 Bargaining Power of Buyers
     3.3.3 Threat of New Entrants
     3.3.4 Threat of Substitutes
     3.3.5 Competitive Rivalry
3.4 Overview of PGD
     3.4.1 Indications and Conditions for PGD
     3.4.2 Primary Candidates for PGD
     3.4.3 Complications Associated with PGD
     3.4.4 Advantages and Disadvantages
     3.4.5 Techniques used for PGD (e.g. FISH, PCR, CGH, etc.)
     3.4.6 Limitations of Techniques
     3.4.7 Risk of PGD
     3.4.8 Average Cost Analysis
3.5 Regulatory Policies and Legality Framework for PGD: Major Countries of Asia
3.6 Market Attractiveness Analysis: Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography, 2014
3.7 Heat map analysis for key market players
3.8 Number of PGD centers, By Country

Chapter 4 Asia Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million), by Test Type, 2013 – 2023
4.1 Overview
4.2 Aneuploidy Screening 
4.3 Chromosomal Aberrations 
4.4 Gender Selection 
4.5 HLA Typing 
4.6 Single Gene Disorder 
4.7 X-linked diseases 

Chapter 5 Asia Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million), by End-user, 2013 – 2023
5.1 Overview
5.2 Fertility Clinics 
5.3 Healthcare Facilities
5.4 Academic Institutes and Research Centers 

Chapter 6 Asia Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million), by Geography, 2013 – 2023
6.1 Overview
6.2 South Eastern Asia
     6.2.1 Indonesia
     6.2.2 Malaysia
     6.2.3 Philippines
     6.2.4 Singapore
     6.2.5 Thailand
     6.2.6 Rest of SEA
6.3 Eastern Asia
     6.3.1 China
     6.3.2 Japan
     6.3.3 South Korea
     6.3.4 Rest of Eastern Asia
6.4 Southern Asia
     6.4.1 India
     6.4.2 Sri Lanka
     6.4.3 Rest of Southern Asia
6.5 Central Asia
6.6 Western Asia
     6.6.1 Israel
     6.6.2 Turkey
     6.6.3 Jordan
     6.6.4 Saudi Arabia
6.6.5 United Arab Emirates
     6.6.6 Rest of Western Asia

Chapter 7 Current Trends and Recommendations

Chapter 8 Company Profiles
8.1 Genesis Genetics
     8.1.1 Company Overview
     8.1.2 Financial Overview
     8.1.3 Product Portfolio
     8.1.4 Business Strategies
     8.1.5 Recent Developments
8.2 Genea Ltd.
8.3 Illumina, Inc.
8.4 Laboratory Corporation of America Holdings (LabCorp)
8.5 Natera, Inc
8.6 PerkinElmer, Inc.
8.7 Quest Diagnostics, Inc.
8.8 Repro Genetics
8.9 Reproductive Genetics Innovations
8.10 Others

Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro in order to eliminate a genetic condition in case a high risk of that condition is known. PGD is an evolving technique that provides a practical alternative to prenatal diagnosis and termination of pregnancy for couples who are at substantial risk of transmitting a serious genetic disorder to their offspring. Growing incidence of infertility across the world is the major driver of the PGD market. Preimplantation genetic diagnosis plays an important role in the detection and determination of genetic disorders, sex-linked diseases, and chromosomal abnormalities in the embryo before IVF can be performed. Rising incidence of infertility coupled with growing awareness about IVF and PGD is the major factor driving the PGD market in Asia. 

The preimplantation genetic diagnosis (PGD) market in Asia has been segmented based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The market analysis is based on market size and forecast in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) for the period 2015 to 2023, considering 2014 as the base year. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers. 

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes Porter’s Five Forces Analysis, overview of PGD, Regulatory Policies and Legality Framework for PGD, Heat Map Analysis for key market players, and country-wise number of PGD Centers in Asia. The report provides a detailed industry analysis of the preimplantation genetic diagnosis (PGD) market in Asia with the help of market attractiveness analysis, by geography, for the year 2014. 

The market has been analyzed for Asia covering South Eastern Asia, Eastern Asia, Southern Asia, Central Asia, and Western Asia. The market size and forecast of the regional and country-wise markets is provided for the period 2013 to 2023. CAGR (%) for each region is also estimated for the period 2015 to 2023, considering 2014 as the base year. South Eastern Asia includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Rest of SEA. Eastern Asia comprises China, Japan, South Korea, and Rest of Eastern Asia. Southern Asia constitutes India, Sri Lanka, and Rest of Southern Asia. Western Asia includes Israel, Turkey, Jordan, Saudi Arabia, the United Arab Emirates, and Rest of Western Asia. Eastern Asia accounted for the largest share of the PGD market in Asia. 

The report also provides recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the PGD market in Asia. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc.(U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.). The market share analysis of key players involved the study of company products or services portfolio, post sales services and maintenance, sales revenue, and its geographical presence. 

The PGD market in Asia has been segmented as follows:

  • Asia Preimplantation Genetic Diagnosis (PGD) Market, by Test Type
    • PGD for Aneuploidy Screening
    • PGD for Chromosomal Aberrations
    • PGD for Gender Selection
    • PGD for HLA Typing
    • PGD for Single Gene Disorder
    • PGD for X-linked diseases
  • Asia Preimplantation Genetic Diagnosis (PGD) Market, by End-user
    • Fertility Clinics
    • Health Care Facilities (including hospitals, diagnostic centers, and health care facilities)
    • Academic Institutes and Research Centers
  • Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography
    • South Eastern Asia
      • Indonesia
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Rest of SEA
    • Eastern Asia
      • China
      • Japan
      • South Korea
      • Rest of Eastern Asia
    • Southern Asia
      • India
      • Sri Lanka
      • Rest of Southern Asia
    • Central Asia
    • Western Asia
      • Israel
      • Turkey
      • Jordan
      • Saudi Arabia
      • United Arab Emirates
      • Rest of Western Asia


 
 
Back To Top